KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

P J de Kam, S Zielen, J A Bernstein, U Berger, M Berger, M Cuevas, D Cypcar, A Fuhr-Horst, W A Greisner, M Jandl, S Laßmann, M Worm, J Matz, E Sher, C Smith, G C Steven, R Mösges, M H Shamji, L DuBuske, F Borghese, K Oluwayi, T Zwingers, M Seybold, O Armfield, M D Heath, S J Hewings, M F Kramer, M A Skinner

Allergy 78(10) 2756-2766

PMID37366581
PMCID-
DOI10.1111/all.15788
发表日期2023-06-27
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: A modified grass allergen subcutaneous immunotherapy (SCIT) product with MicroCrystalline Tyrosine and monophosphoryl lipid-A as an adjuvant system (Grass MATA MPL [PQ Grass]) is being developed as short-course treatment of grass-pollen allergic rhinitis (SAR) and/or rhinoconjunctivitis. We sought to evaluate the combined symptom and medication score (CSMS) of the optimized cumulative dose of 27,600 standardized units (SU) PQ Grass in a field setting prior to embarking on a pivotal Phase III trial. METHODS: In this exploratory, randomized, double-blind, placebo-controlled trial subjects were enrolled across 14 sites (Germany and the United States of America). Six pre-seasonal subcutaneous injections of PQ Grass (using conventional or extended regimens) or placebo were administered to 119 subjects (aged 18-65 years) with moderate-to-severe SAR with or without asthma that was well-controlled. The primary efficacy endpoint was CSMS during peak grass pollen season (GPS). Secondary endpoints included Rhinoconjunctivitis Quality of Life Questionnaire standardized (RQLQ-S) and allergen-specific IgG4 response. RESULTS: The mean CSMS compared to placebo was 33.1% (p = .0325) and 39.5% (p = .0112) for the conventional and extended regimens, respectively. An increase in IgG4 was shown for both regimens (p < .01) as well as an improvement in total RQLQ-S for the extended regimen (mean change -0.72, p = .02). Both regimens were well-tolerated. CONCLUSIONS: This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to ≈40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well-tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。